| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 19 May 2026 | 8 May 2026 |
| Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/05/2026 ,inter alia, to consider and approve audited financial results for the quarter / year ended on March 31, 2026, and to recommend final dividend for the Financial Year ended March 31, 2026. Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/05/2026 ,inter alia, to consider and approve Update on board meeting (As Per BSE Annoncement Dated on:13.05.2026) Audited financial results for the quarter / year ended on March 31, 2026 Change in Director (As per BSE Announcement dated on: 19.05.2026) | ||
| Board Meeting | 9 Feb 2026 | 27 Jan 2026 |
| Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/02/2026 inter alia to consider and approve Unaudited Financial Results for the quarter / nine months ended on December 31 2025. Unaudited Financial Results for the quarter and nine months ended on December 31, 2025. (As per BSE announcement dated on : 09.02.2026) | ||
| Board Meeting | 6 Nov 2025 | 29 Oct 2025 |
| Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2025 ,inter alia, to consider and approve unaudited financial results for the quarter / half year ended on September 30, 2025. Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2025 ,inter alia, to consider and approve To consider fund raising (As Per BSE Announcement Dated on:03.11.2025) Unaudited financial results for the quarter and half year ended on September 30, 2025 Outcome of Board Meeting (As Per BSE Announcement Dated on:06.11.2025) | ||
| Board Meeting | 12 Aug 2025 | 1 Aug 2025 |
| Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2025 inter alia to consider and approve unaudited financial results for the quarter ended on June 30 2025. Unaudited financial results for the quarter ended on June 30, 2025 (As Per BSE Announcement Dated on: 12/08/2025) | ||
| Board Meeting | 16 Jun 2025 | 16 Jun 2025 |
| Change in Senior Management | ||
Zydus Life stated that it has unveiled the biosimilar under the brand Tishtha™. It can be used for treatment of multiple cancers.
It further added that the company will raise funds via qualified institutional placement (QIP) to part-fund the acquisition.
NUFYMCO is a vascular endothelial growth factor inhibitor designed to treat serious ophthalmic conditions, particularly those affecting retinal health.
Here are some of the stocks that may see significant price movement today: HCL Technologies, Zydus Lifesciences, Intellect Design Arena, etc.
The company plans to manufacture these tablets at its formulation manufacturing facility situated in the SEZ in Ahmedabad.
Ravishanker Kovi, the founder and executive chairman of RK Pharma, commented that Zydus Life has a powerful commercial footprint.
The approved product is a biosimilar of the US reference listed drug Calan SR extended-release tablets in the same vials.
The product is a generic version of Lynparza Tablets developed by AstraZeneca.
Here are some of the stocks that may see significant price movement: Bharti Airtel, Cipla, Gland Pharma, etc.
Here are some of the stocks that may see significant price movement today: Tata Motors, TVS Motors, Zydus Lifesciences, etc.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
